Trial Profile
Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms API-CAT
- 11 Sep 2023 Planned End Date changed from 30 Oct 2024 to 6 Oct 2024.
- 11 Sep 2023 Planned primary completion date changed from 30 Sep 2023 to 6 Sep 2024.
- 11 Sep 2023 Status changed from recruiting to active, no longer recruiting.